This HTML5 document contains 159 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n29http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n28http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00908/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00908/identifier/wikipedia/
n9http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/mixture/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00908/identifier/kegg-compound/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00908/identifier/pubchem-compound/
n31http://bio2rdf.org/drugbank:
n24http://linked.opendata.cz/resource/drugbank/drug/DB00908/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00908/identifier/iuphar/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00908/identifier/drugbank/
n10http://www.rxlist.com/cgi/generic/
n32http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00908/identifier/guide-to-pharmacology/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00908/identifier/national-drug-code-directory/
n27http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n7http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00908/identifier/chemspider/
n17http://linked.opendata.cz/resource/atc/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00908/identifier/chebi/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00908
rdf:type
n3:Drug
n3:description
An optical isomer of quinine, extracted from the bark of the Cinchona tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular action potential, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission. [PubChem]
n3:dosage
n9:271B5DB8-363D-11E5-9242-09173F13E4C5 n9:271B5DB9-363D-11E5-9242-09173F13E4C5 n9:271B5DBA-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
6-8 hours
n3:indication
For the treatment of ventricular pre-excitation and cardiac dysrhythmias
n3:manufacturer
n5:271B5DA5-363D-11E5-9242-09173F13E4C5 n5:271B5DA6-363D-11E5-9242-09173F13E4C5 n5:271B5DA3-363D-11E5-9242-09173F13E4C5 n5:271B5DA4-363D-11E5-9242-09173F13E4C5 n5:271B5DA9-363D-11E5-9242-09173F13E4C5 n5:271B5DAA-363D-11E5-9242-09173F13E4C5 n5:271B5DA7-363D-11E5-9242-09173F13E4C5 n5:271B5DA8-363D-11E5-9242-09173F13E4C5 n5:271B5DAD-363D-11E5-9242-09173F13E4C5 n5:271B5DAE-363D-11E5-9242-09173F13E4C5 n5:271B5DAB-363D-11E5-9242-09173F13E4C5 n5:271B5DAC-363D-11E5-9242-09173F13E4C5 n5:271B5DAF-363D-11E5-9242-09173F13E4C5 n5:271B5D96-363D-11E5-9242-09173F13E4C5 n5:271B5D99-363D-11E5-9242-09173F13E4C5 n5:271B5D9A-363D-11E5-9242-09173F13E4C5 n5:271B5D97-363D-11E5-9242-09173F13E4C5 n5:271B5D98-363D-11E5-9242-09173F13E4C5 n5:271B5D9D-363D-11E5-9242-09173F13E4C5 n5:271B5D9E-363D-11E5-9242-09173F13E4C5 n5:271B5D9B-363D-11E5-9242-09173F13E4C5 n5:271B5D9C-363D-11E5-9242-09173F13E4C5 n5:271B5DA1-363D-11E5-9242-09173F13E4C5 n5:271B5DA2-363D-11E5-9242-09173F13E4C5 n5:271B5D9F-363D-11E5-9242-09173F13E4C5 n5:271B5DA0-363D-11E5-9242-09173F13E4C5 n5:271B5D8C-363D-11E5-9242-09173F13E4C5 n5:271B5D8D-363D-11E5-9242-09173F13E4C5 n5:271B5D8B-363D-11E5-9242-09173F13E4C5 n5:271B5D90-363D-11E5-9242-09173F13E4C5 n5:271B5D91-363D-11E5-9242-09173F13E4C5 n5:271B5D8E-363D-11E5-9242-09173F13E4C5 n5:271B5D8F-363D-11E5-9242-09173F13E4C5 n5:271B5D94-363D-11E5-9242-09173F13E4C5 n5:271B5D95-363D-11E5-9242-09173F13E4C5 n5:271B5D92-363D-11E5-9242-09173F13E4C5 n5:271B5D93-363D-11E5-9242-09173F13E4C5
owl:sameAs
n31:DB00908 n32:DB00908
dcterms:title
Quinidine
adms:identifier
n12:Quinidine n14:389880 n15:DB00908 n18:28593 n19:2342 n20:C06527 n21:2342 n23:441074 n24:46505356 n25:53489-459-02 n26:PA451209
n3:mechanismOfAction
Quinidine acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Quinidine may also act on the slow inward calcium current (ICa), the rapid (IKr) and slow (IKs) components of the delayed potassium rectifier current, the inward potassium rectifier current (IKI), the ATP-sensitive potassium channel (IKATP) and Ito.
n3:packager
n5:271B5D82-363D-11E5-9242-09173F13E4C5 n5:271B5D83-363D-11E5-9242-09173F13E4C5 n5:271B5D80-363D-11E5-9242-09173F13E4C5 n5:271B5D81-363D-11E5-9242-09173F13E4C5 n5:271B5D7E-363D-11E5-9242-09173F13E4C5 n5:271B5D7F-363D-11E5-9242-09173F13E4C5 n5:271B5D7C-363D-11E5-9242-09173F13E4C5 n5:271B5D7D-363D-11E5-9242-09173F13E4C5 n5:271B5D7A-363D-11E5-9242-09173F13E4C5 n5:271B5D7B-363D-11E5-9242-09173F13E4C5 n5:271B5D88-363D-11E5-9242-09173F13E4C5 n5:271B5D89-363D-11E5-9242-09173F13E4C5 n5:271B5D86-363D-11E5-9242-09173F13E4C5 n5:271B5D87-363D-11E5-9242-09173F13E4C5 n5:271B5D84-363D-11E5-9242-09173F13E4C5 n5:271B5D85-363D-11E5-9242-09173F13E4C5 n5:271B5D8A-363D-11E5-9242-09173F13E4C5 n5:271B5D78-363D-11E5-9242-09173F13E4C5 n5:271B5D79-363D-11E5-9242-09173F13E4C5 n5:271B5D76-363D-11E5-9242-09173F13E4C5 n5:271B5D77-363D-11E5-9242-09173F13E4C5 n5:271B5D74-363D-11E5-9242-09173F13E4C5 n5:271B5D75-363D-11E5-9242-09173F13E4C5 n5:271B5D72-363D-11E5-9242-09173F13E4C5 n5:271B5D73-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
When the urine pH is less than 7, about 20% of administered quinidine appears unchanged in the urine, but this fraction drops to as little as 5% when the urine is more alkaline.
n3:synonym
Chinidinum CIN-QUIN (S)-(6-Methoxyquinolin-4-yl)((2R,5R)-5-vinylquinuclidin-2-yl)methanol (+)-quinidine Conchinin Quinidina Kinidin beta-Quinine Conquinine (8R,9S)-Quinidine 6-Methoxy-alpha-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol (R)-(6-Methoxyquinolin-4-yl)((3S,4R,7S)-3-vinylquinuclidin-7-yl)methanol Chinidin β-quinine (S)-(6-Methoxy-quinolin-4-yl)-((2R,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol Pitayine alpha-(6-Methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol Quinidine
n3:volumeOfDistribution
* 2 to 3 L/kg * 0.5 L/kg [congestive heart failure] * 3 to 5 L/kg [cirrhosis of the liver]
n16:hasAHFSCode
n29:24-04-04-04
n3:foodInteraction
Preferably take on an ampty stomach.
n3:mixture
n13:271B5D71-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
80-88%
n3:salt
n3:synthesisReference
Jean Paul REMON, Chris Vervaet, "QUININE AND QUINIDINE SALTS, METHODS FOR MAKING THEM, AND PHARMACEUTICAL FORMULATIONS COMPRISING THEM." U.S. Patent US20090239900, issued September 24, 2009.
n27:hasConcept
n28:M0018341
foaf:page
n7:quinidine-gluconate-controlled-release-tablets.html n10:quinidine.htm
n3:IUPAC-Name
n4:271B5DBF-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5DC5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5DC4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5DC1-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5DC2-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5DC3-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5DD5-363D-11E5-9242-09173F13E4C5 n4:271B5DBD-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5DD7-363D-11E5-9242-09173F13E4C5 n4:271B5DBE-363D-11E5-9242-09173F13E4C5 n4:271B5DBB-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5DBC-363D-11E5-9242-09173F13E4C5 n4:271B5DD8-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B5DDA-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n17:C01BA01
n3:H-Bond-Acceptor-Count
n4:271B5DCB-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5DCC-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5DC6-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5DC7-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5DC9-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5DC8-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5DCA-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:caco2-Permeability
n4:271B5DD9-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
56-54-2
n3:category
n3:clearance
* 3 – 5 mL/min/kg [adults]
n3:containedIn
n8:271B5DB3-363D-11E5-9242-09173F13E4C5 n8:271B5DB4-363D-11E5-9242-09173F13E4C5 n8:271B5DB1-363D-11E5-9242-09173F13E4C5 n8:271B5DB2-363D-11E5-9242-09173F13E4C5 n8:271B5DB0-363D-11E5-9242-09173F13E4C5 n8:271B5DB7-363D-11E5-9242-09173F13E4C5 n8:271B5DB5-363D-11E5-9242-09173F13E4C5 n8:271B5DB6-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5DD1-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5DD3-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5DD4-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5DD6-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5DD0-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5DCF-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5DD2-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5DC0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5DCD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5DCE-363D-11E5-9242-09173F13E4C5